What are the side effects of denosumab?

Side Effects of Denosumab

Denosumab is generally well-tolerated with common side effects including arthralgia, nasopharyngitis, and hypocalcemia, but carries serious risks including hypocalcemia (especially in renal disease), osteonecrosis of the jaw, atypical femoral fractures, serious infections, and a critical rebound effect with multiple vertebral fractures upon discontinuation.

Common Side Effects

The most frequently reported adverse effects in clinical trials include 1, 2:

• Musculoskeletal: Arthralgia, extremity pain, back pain, myalgia, bone pain
• Upper respiratory: Nasopharyngitis, upper respiratory infection
• Gastrointestinal: Constipation
• Genitourinary: Urinary tract infection
• Dermatologic: Rash, eczema (118 cases vs 65 in placebo over 3 years)
• General: Headache

Importantly, overall serious adverse event rates (23.8% vs 23.9%) and discontinuation rates (2.4% vs 2.1%) were similar to placebo in the FREEDOM trial 1.

Serious Adverse Effects

Hypocalcemia (Most Critical Metabolic Risk)

Hypocalcemia is the most important metabolic complication, particularly life-threatening in patients with chronic kidney disease 3, 2:

• Normal renal function: ~0.05% risk (2 of 4,050 patients in large trials)
• Advanced CKD (eGFR <30 mL/min) or dialysis: 14-25% risk
• Severe cases: Can result in hospitalization, life-threatening events, and death

Key risk factors 3, 2:

• Chronic kidney disease (CKD-MBD/renal osteodystrophy markedly increases risk)
• Vitamin D deficiency at baseline
• High baseline bone turnover markers
• Concomitant calcimimetic drug use

Management requirements 4, 2:

• Correct hypocalcemia BEFORE starting denosumab
• Ensure adequate calcium and vitamin D supplementation
• Monitor calcium levels within 14 days of injection in high-risk patients
• Check calcium, phosphorus, and magnesium in CKD patients

Osteonecrosis of the Jaw (ONJ)

Occurs in 1-2% of patients receiving denosumab for cancer-related bone disease 4. Risk is dose-dependent:

• Osteoporosis dosing (60 mg every 6 months): Very low risk, similar to bisphosphonates 1
• Cancer dosing (120 mg monthly): 5% incidence in D-CARE trial 5

Prevention strategies 4, 6:

• Oral examination before therapy initiation
• Maintain good oral hygiene during treatment
• Avoid invasive dental procedures (extractions, implants) during therapy
• If dental surgery necessary, defer denosumab until complete healing confirmed
• Prophylactic antibiotics if extraction unavoidable

Serious Infections

Denosumab increases risk of serious infections 3:

• Meta-analysis: Relative risk 1.23 (95% CI 1.00-1.52, P=0.05) for serious infection-related adverse events 3
• Skin infections: Erysipelas and cellulitis occurred in 0.4% (15 patients) vs <0.1% (1 patient) on placebo 3
• Other sites: GI tract, urinary tract, heart, ear (numerically higher but not statistically significant)
• Serious opportunistic/fatal infections: Rare and not significantly different from placebo

Mechanism: Denosumab affects immune system function; patients with weakened immunity or on immunosuppressive medications have increased risk 2.

Atypical Femoral Fractures (AFFs)

Rare but serious complication associated with long-term use 6, 2:

• Absolute risk: 3.2-50 per 100,000 person-years
• Long-term use: Up to 100 per 100,000 person-years (median 7 years exposure)
• Clinical features: Prodromal thigh/hip/groin pain, transverse fracture line, minimal comminution, bilateral risk

Patient counseling: Advise patients to report new or unusual thigh, hip, or groin pain 2.

Rebound Effect Upon Discontinuation (CRITICAL)

This is the most clinically significant concern with denosumab and distinguishes it from bisphosphonates 3, 7, 3:

Mechanism and timeline 3:

• Bone turnover markers (CTX, P1NP) increase above baseline within 3-6 months of discontinuation
• BMD declines to pretreatment levels within 18-24 months
• Effects reverse rapidly because denosumab does NOT incorporate into bone (unlike bisphosphonates)

Vertebral fracture risk 3:

• Risk of multiple and/or severe vertebral fractures (~20% in some reports)
• Fractures can occur even in patients without prior vertebral fractures
• Risk does not usually exceed baseline fracture rate but represents excess occurrence vs placebo
• Longer denosumab treatment duration increases rebound severity

Critical management principle 3, 7, 2:

• DO NOT interrupt or delay doses - maintain strict every-6-month schedule
• DO NOT discontinue without transition therapy
• If stopping necessary, transition to bisphosphonate (typically high-dose zoledronic acid) to maintain bone turnover suppression
• Drug holidays are NOT recommended for denosumab (unlike bisphosphonates)

Dermatologic Reactions

• Eczema: Higher incidence (118 vs 65 cases over 3 years) 3
• Rash: Increased rate in pooled analysis 1
• Serious skin events (erysipelas, cellulitis): 0.4% vs <0.1% 3

Patients should seek prompt medical attention for dermatological reactions 2.

Other Adverse Effects

Musculoskeletal Pain

Severe bone, joint, and/or muscle pain reported; patients should report severe symptoms 2.

Malignancy

No increased risk detected in clinical trials 3.

Delayed Fracture Healing

No statistically significant risk in FREEDOM trial 3.

Hypersensitivity Reactions

Serious allergic reactions can occur including hypotension, throat tightness, swelling, rash 2. Contraindicated in patients with prior systemic hypersensitivity to denosumab.

Special Population Considerations

Chronic Kidney Disease

• Can be used in CKD (unlike bisphosphonates which require dose adjustment/discontinuation)
• Severe CKD (eGFR <30) or dialysis: Markedly increased hypocalcemia risk
• Requires intensive calcium monitoring and supplementation 4, 3, 4, 2

Pregnancy and Lactation

• Contraindicated in pregnancy - can cause fetal harm 2
• Verify pregnancy status before initiating
• Use effective contraception during therapy and for ≥5 months after last dose
• Advise against breastfeeding during treatment 2

Pediatric Use

• Not established for safety/efficacy in children
• Hypercalcemia reported in pediatric osteogenesis imperfecta patients (some requiring hospitalization with acute renal injury)
• May impair long-bone growth and tooth eruption in children <4 years 2

Clinical Monitoring Recommendations

Before initiating 4, 2:

• Dental examination (high-risk patients)
• Correct pre-existing hypocalcemia
• Ensure adequate calcium/vitamin D status

During treatment 4, 2:

• Calcium supplementation (mandatory)
• Vitamin D supplementation (mandatory)
• Monitor calcium within 14 days of injection in high-risk patients
• Monitor calcium, phosphorus, magnesium in CKD patients
• Maintain strict every-6-month dosing schedule

Key pitfall: The reversible nature of denosumab's effects makes adherence to dosing schedule and transition planning absolutely critical - this is fundamentally different from bisphosphonates and represents the major limitation of this otherwise effective agent.